Close
RNS Number : 5373M
Alliance Pharma PLC
11 May 2020
 

 

 

                                            11 May 2020

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Director's Dealing

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that it has received notice that on 7 May 2020, Peter Butterfield, Chief Executive Officer of Alliance, exercised unapproved share options over 200,000 Ordinary Shares of 1p each in the Company ("Ordinary Shares") under the Company's Share Option Plans. The exercise price was 47.5 pence per share.

Following the exercise, Mr Butterfield retained 38,085 Ordinary Shares. Mr Butterfield sold 161,915 Ordinary Shares at a price of 74.7 pence per share to cover the associated exercise costs and tax liability arising on the exercise of the options. Following these transactions, Mr Butterfield's total beneficial interest in the Group is 412,461 Ordinary Shares, representing approximately 0.08 per cent. of the Group's issued share capital.

 

The 200,000 Ordinary Shares will be admitted to trading pursuant to an existing block listing and will rank pari passu with the existing Ordinary Shares in issue.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Peter Butterfield

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ALLIANCE PHARMA PLC

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 

GB0031030819

b)

Nature of the transaction

a)   Exercise of options

b)   Sale of Ordinary Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

a)   47.5 pence

b)   74.7 pence

 

a) 200,000

b) 161,915

 

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

f)

Date of the transaction(s)

7 May 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information:

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

 

Corporate Broking: Patrick Robb / Tejas Padalkar

 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGPUPCAUPUGCG